PARP1 and head and neck squamous cell carcinoma: Studies have therefore suggested that PARP inhibitors can be utilised to further radiosensitise HPV-positive OPSCC cells as a consequence of the persistence of DSBs, although data have interestingly also revealed this to be an effective approach in cells from HPV-negative HNSCC even though these are DSB repair proficient (reviewed in (18)).